Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007065 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
A Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 561
- Enrollment target
- 20
- Study locations
NCT07007065 is a Phase 3 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by AbbVie. The registered enrollment target is 561 participants, above the 392-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07007065, a Phase 3 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 561 participants
- Enrollment target
- 20
- Study locations
Study Summary
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide. Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Surabgene Lomparvovec (ABBV-RGX-314)
- DRUG Ranibizumab Control
Study Locations (20)
California
- Retinal Diagnostic Center /ID# 263054 - Campbell
- The Retina Partners /ID# 263265 - Encino
- Retina Associates of Southern California /ID# 263056 - Huntington Beach
- Retinal Consultants - Sacramento - Greenback Lane /ID# 263983 - Sacramento
- Orange County Retina Medical Group /ID# 266612 - Santa Ana
Colorado
- Retina Consultants of Southern Colorado /ID# 263284 - Colorado Springs
- Colorado Retina Associates /ID# 263247 - Lakewood
- Advanced Vision Surgery Center /ID# 264208 - Longmont
Florida
- Advanced Research, LLC /ID# 276526 - Deerfield Beach
- Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631 - Fort Myers
- Florida Retina Institute - Lake Mary /ID# 263288 - Lake Mary
Maryland
- The Retina Care Center /ID# 263263 - Baltimore
- Retina Specialist /ID# 264633 - Towson
Arizona
- American Vision Partners /ID# 264615 - Sun City
Georgia
- Southeast Retina Center /ID# 263264 - Augusta
Illinois
- Springfield Clinic Main Campus /ID# 265202 - Springfield
Indiana
- Midwest Eye Institute North Indianapolis /ID# 264031 - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 561 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2033-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007065
The ClinicalTrials.gov registry entry for NCT07007065 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 561 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 392-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (43% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Surabgene Lomparvovec (ABBV-RGX-314) is the first listed.
NCT07007065 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT07007065 about?
NCT07007065 is a clinical study titled "Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)". Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating partici...
What is the current status of trial NCT07007065?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 561 participants. The study started on 2025-11-05. Estimated completion is 2033-03.
What conditions does trial NCT07007065 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT07007065?
The interventions under investigation include: Surabgene Lomparvovec (ABBV-RGX-314) (DRUG), Ranibizumab Control (DRUG).
Who is sponsoring clinical trial NCT07007065?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007065 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Extension Study for the Port Delivery System With Ranibizumab (Portal)
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.